Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
SPECIAL FEATURE - Analytical Testing – Diverse Demands & Therapies Require Diverse Analyses February 11, 2025
Contributor Cindy H. Dubin highlights how analytical testing has evolved to address diverse pharmaceutical therapeutics in research and development.
MICRONEEDLE MANUFACTURING - The Value of a Manufacturing-Oriented Microneedle Mindset February 10, 2025
Andrew Riso says despite the significant buzz surrounding microneedle technology, a considerable gap remains between innovations and market-ready products. While early stage development and preclinical studies have shown promising results, the challenge of translating these advancements into scalable, commercially viable products persists.
NEW PRODUCT INTRODUCTION - Addressing the Pitfalls of Progressing From Pilot to Product Through Effective New Product Introduction February 10, 2025
Uwe Hanenberg, PhD, Wolfram Bühler, and Radoslaw Kaczanowski, PhD, explore the risks and challenges pharmaceutical companies face when undertaking NPI to ensure new products successfully reach the market and patients and examine the strategies CDMOs are adopting to ensure the smooth delivery of these projects from discovery to commercialization.
Sanara MedTech Inc. Announces Exclusive License & Distribution Agreement With & Minority Investment in Biomimetic Innovations Ltd January 22, 2025
Sanara MedTech Inc. recently announced the execution of an exclusive license and distribution agreement with Biomimetic Innovations Ltd. In tandem,...Inmagene Reports Positive Topline Results of a Nondepleting Anti-OX40 Monoclonal Antibody With an Extended Half-Life for the Treatment of Atopic Dermatitis January 9, 2025
Inmagene Biopharmaceuticals reports additional positive topline results from the Phase 2a trial of IMG-007 in patients with moderate-to-severe AD, along...Silo Pharma Awarded Patent for Groundbreaking PTSD Treatment January 8, 2025
Silo Pharma, Inc. recently announced the US Patent and Trademark Office (USPTO) issued a Notice of Allowance for patent application...Ikena Oncology & Inmagene Biopharmaceuticals Announce Agreement for Merger & Private Placement December 23, 2024
Ikena Oncology, Inc. and Inmagene Biopharmaceuticals recently announced they have entered into a definitive merger agreement. In connection with the...ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative December 19, 2024
ABVC BioPharma, Inc. recently announced in response to the discontinuation of Prozac due to increasing concerns around side effects, ABVC...SCYNEXIS Initiates Dosing in Phase 1 Trial of a Second-Generation Fungerp Candidate for Invasive Fungal Infections December 18, 2024
SCYNEXIS, Inc. recently announced it has completed the dosing of the first cohort of subjects in its Phase 1 trial...EXECUTVE INTERVIEW - MediWound Ltd.: Developing a New Class of Biologic Enzymatic Therapeutic Products to Debride Wounds October 9, 2024
MediWound (Nasdaq: MDWD) specializes in the development, production and commercialization of rapid and effective biologics that improve existing standards of wound care. The company aims to enhance patient experiences while reducing costs and unnecessary surgeries.
HBC Immunology Completes In Vivo Drug Lead Studies for Prostrate Cancer Treatment October 9, 2024
HBC Immunology (HBCI) recently announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a...Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, an Oral Mpro Inhibitor September 30, 2024
Traws Pharma, Inc. recently announced positive topline Phase 1 results for its potential best-in-class COVID (SARS-CoV-2) candidate, ratutrelvir, an oral...Tiziana Life Sciences Announces $4-Million Grant to Study Anti-CD3 in Alzheimer’s Disease September 19, 2024
Tiziana Life Sciences, Ltd. recently announced the National Institutes of Health (NIH), National Institute on Aging have awarded a $4-million...Orbis Medicines & Vivtex Form Research & Exclusive Licensing Collaboration September 17, 2024
Orbis Medicines recently announced a research collaboration and option to an exclusive license with Vivtex, a biotech company aiming to...TFF Pharmaceuticals Announces Positive Preclinical Data From Bivalent Universal Influenza Vaccine Candidates September 11, 2024
TFF Pharmaceuticals, Inc recently announced positive preclinical data advancing a multivalent universal influenza vaccine manufactured by TFF to protect against...BriaCell Reports Positive Overall Survival in Metastatic Breast Cancer September 11, 2024
BriaCell Therapeutics Corp. recently announced positive overall survival data of its Phase 2 clinical study of Bria-IMT in combination with...SPECIAL FEATURE - Injection Devices: From Pens & Autoinjectors to Pills, Sprays & Capsules, Injections Become More Efficient September 6, 2024
Contributor Cindy H. Dubin reports on innovative and promising injection technologies that are ever more user friendly, versatile, precise, and life-saving.
SILICON-STABILIZED HYBRID LNPS - Next-Generation Delivery of RNA Therapeutics September 5, 2024
Suzanne Saffie-Siebert, PhD, Michael Welsh, PhD, Nissim Torabi-Pour, PhD, and Flavia M. Sutera, PhD, review current shortcomings, as well as some accompanying manufacturing challenges, and will show how they can be addressed by SiSaf’s silicon-stabilized hybrid LNPs.
ST Pharm & Quantoom Biosciences Announce First Supply Agreement of SmartCap Under Extended Collaboration to Advance RNA Manufacturing August 20, 2024
ST Pharm and Quantoom Biosciences recently announced an extended collaboration to accelerate the development and manufacturing of RNA-based vaccines and...NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02 for Patients Afflicted With Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate August 5, 2024
NeOnc Technologies Holdings, Inc. has begun patient enrollment for the Phase 2 clinical trial of NEO100-02, the company’s first of...Company Profiles
Lyophilization Technology, Inc.
Lyophilization Technology, Inc. 30 Indian Drive Ivyland, PA 18974-1431 T: (215) 396-8373 F: (215) 396-8375 E: inquiry@lyo-t.com W: www.lyotechnology.com WHO...DRUG-DEVICE DEVELOPMENT - Exploring the Complexities of Drug-Device Combination Products
Jeremy Guo, Senior Vice President at WuXi Biologics, and colleagues explain that many factors need to be taken into account when producing a Drug-Device Combination Product from development testing to fill/finish and assembly.
